Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Daré Announces Two Late-Breaking Abstracts to be Presented at the American Association of Pharmaceutical Scientists (AAPS) in Washington D.C.
SAN DIEGO , Oct. 30, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a clinical-stage, women’s biopharmaceutical company, today announced that it will be presenting two late-breaking abstracts at the upcoming Association of Pharmaceutical Scientists (AAPS) meeting taking place
View HTML
Toggle Summary Daré Bioscience Announces Publication of Pharmacokinetics Study of DARE-HRT1, a Potential Hormone Replacement Therapy, in the Journal of Pharmaceutical Sciences
SAN DIEGO , April 08, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced the article entitled “Pharmacokinetics and tolerability of a novel 17β-estradiol and progesterone intravaginal ring in sheep” was published online in the
View HTML
Toggle Summary Daré Bioscience Announces Publication of Positive Clinical Findings for Vaginal Administration of Tamoxifen for the Treatment of VVA
DARE-VVA1 is a proprietary formulation of tamoxifen for vaginal administration as a potential treatment for VVA in patients with hormone-receptor-positive breast cancer SAN DIEGO , March 18, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today
View HTML
Toggle Summary Daré Bioscience Announces the Publication of a Pharmacokinetics Study of DARE-FRT1, a Potential Therapy for Preterm Birth and Fertility, in Drug Delivery and Translational Research
SAN DIEGO, May 8, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced the article entitled “Pharmacokinetics and tolerability of a novel progesterone intravaginal ring in sheep” was published online in the journal Drug Delivery and
View HTML
Toggle Summary Daré Bioscience Provides Business Update and Announces Third Quarter Financial Results
SAN DIEGO , Nov. 13, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a clinical-stage, women’s biopharmaceutical company, today provided a business update and announced financial results for the three and nine months ended September 30, 2018.
View HTML
Toggle Summary Daré Bioscience Provides Update for Investors on Development Programs and Anticipated 2019 Milestones
Key anticipated 2019 clinical milestones: Topline results of Ovaprene® PCT clinical trial Initiation of at-home portion of Sildenafil Cream, 3.6% Phase 2b Initiation of pivotal Phase 3 study of DARE-BV1 SAN DIEGO , Jan. 02, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc.
View HTML
Toggle Summary Daré Bioscience receives notification of second award from the National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development for the development of Ovaprene®
SAN DIEGO , March 11, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc.  (NASDAQ:DARE), a leader in women’s health innovation, today announced that it received a second Notice of Award of $982,851 , part of a grant providing up to $1.9 million in the aggregate for Ovaprene® research from the Eunice
View HTML
Toggle Summary Daré Bioscience Reports First Quarter 2019 Financial Results and Company Update
SAN DIEGO , May 14, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the first quarter ended March 31, 2019 and provided a Company update. “The first quarter was an active one for Daré and positioned us well
View HTML
Toggle Summary Daré Bioscience to Host First Quarter 2019 Financial Results and Company Update Conference Call and Webcast
SAN DIEGO , May 07, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc.(NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Tuesday, May 14, 2019, to review the Company's financial results for the quarter
View HTML
Toggle Summary Daré Bioscience, Inc. Announces Enrollment in Thermography Feasibility Study with Sildenafil Cream, 3.6%, a Potential Therapy for Female Sexual Arousal Disorder
Sildenafil Cream, 3.6% has the Potential to Receive the First FDA Approval for Female Sexual Arousal Disorder SAN DIEGO , Nov. 27, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc . (NASDAQ: DARE), a leader in clinical-stage women’s health innovation, today announced that it is currently enrolling
View HTML